> Argenx struck a deal to use Halozyme’s delivery technology to develop subcutaneous formulations of its current and future drug candidates. The biotech paid $30 million (€26 million) upfront to land the deal. Statement
> Newron Pharmaceuticals completed enrollment in its pivotal Rett syndrome trial. The milestone sets Newron up to deliver top-line results before the end of the year. Release
> Sotio named Harald Fricke as its CMO. Fricke last worked at Apogenix, a company he co-founded in 2006. Statement
> Audion Therapeutics posted phase 1 data on its notch inhibitor in patients with mild to moderate sensorineural hearing loss. A phase 2 trial of the drug started last month. Release
> BioLineRx priced $15.4 million worth of shares and warrants. Statement
> UniQure dosed the first patient in its pivotal hemophilia B trial. The gene therapy trial is expected to be fully enrolled by the end of the year. Release